| PHUSE US |
2026 |
Acquiring a Compound with Multiple Clinical Trials? Let's Get Ready for a Type C Meeting! Key Considerations for Preparing Its Regulatory Submission |
Mathura P. Ramanathan,
Kajal Tahiliani |
source
presentation source |
12 |
| PHUSE US |
2026 |
Mapping Minimal Residual Disease (MRD) Biomarker Data in Hematologic Malignancies: Clinical Significance and Data Standards in SDTM and ADaM |
Jyothi Nelakurthi |
source
presentation source |
8 |
| PHUSE EU |
2023 |
Efficacy Endpoints in Adjuvant and Neo-Adjuvant Oncology Trials |
Yuliia (Piddubna) Cherednichenko,
Anna Amosova |
source
presentation source |
15 |
| PHUSE EU |
2022 |
Tumour Assessment Evaluation Using MS Azure and Power BI [presentation] |
Robert Adams,
Clara Beck |
source
video |
22 |
| PharmaSUG |
2020 |
Calculation of Cochran-Mantel-Haenszel Statistics for Objective Response and Clinical Benefit Rates and the Effects of Stratification Factors |
Girish Kankipati,
Chia-Ling (Ally) Wu |
source |
8 |
| PHUSE US |
2020 |
Integration of Biomarkers Data in Clinical Trials |
Prakash Dev |
source
presentation source |
5 |
| PHUSE EU |
2013 |
Efficacy Endpoints in Oncology |
Angelo Tinazzi |
source |
9 |
| PHUSE EU |
2013 |
Oncology Endpoints: An Unexpected Journey |
Waseem Jugon,
Mijanur Rahman |
source |
12 |
| PharmaSUG |
2011 |
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterprise Miner |
Patricia B. Cerrito |
source |
15 |
HOME
QUICK SEARCH
AUTHORS
KEYWORDS
HELP
BUGS